🇺🇸 FDA
Pipeline program

TAK-954

TAK-954-2003

Phase 2 small_molecule completed

Quick answer

TAK-954 for Diabetic Gastroparesis is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Diabetic Gastroparesis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials